Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion—A Phase 2, Prospective Interventional Study

Authors:

Abstract
No abstract available
Funding Information
  • Novartis
  • Gilead Sciences

This publication has 26 references indexed in Scilit: